PCSK9 Protein Identified as Key to Pancreatic Cancer Spread
Table of Contents
Researchers uncover how a specific protein enables pancreatic cancer cells to metastasize to the lungs and liver, paving the way for new treatment strategies.
SAN FRANCISCO – Scientists at UC san Francisco have made a significant breakthrough in understanding how pancreatic cancer cells successfully colonize the lungs and liver. These organs present vastly different environments, yet cancer cells manage to thrive in both. The research highlights the role of a protein called PCSK9 in this process, potentially opening new avenues for treatment.
The study, published in Nature on May 21, reveals that PCSK9 influences how pancreatic cancer cells acquire cholesterol, a crucial adaptation for survival in different organ environments. Pancreatic cancer is known for its resistance to many therapies, making these findings particularly significant.
Researchers sought to identify the factors enabling cancer cells to survive in either the lung or the liver.They analyzed data from MetMap, a project at the Broad Institute, focusing on pancreatic cancer cell lines with a preference for colonizing either organ.By examining genomic differences, they aimed to understand the mechanisms driving this organ preference.
Their analysis revealed that PCSK9 plays a critical role in cholesterol acquisition. When PCSK9 levels are low, cancer cells readily absorb cholesterol from their surroundings, which is abundant in the liver. Conversely, when PCSK9 levels are high, cancer cells produce their own cholesterol and generate molecules that protect them from oxygen damage, an adaptation suited for the lungs.
The team’s experiments demonstrated that manipulating PCSK9 expression could redirect cancer cells to different organs. When pancreatic cancer cells destined for the liver were forced to express PCSK9, they rather migrated to the lungs.
Implications for Treatment
“Cancers persist by adapting to live in new tissues and organs,and we found that pancreatic tumors use PCSK9 to adapt as they spread,” said Rushika Perera,PhD,the Deborah Cowan Endowed Associate Professor of Anatomy at UCSF and senior author of the paper. “It opens the door to fighting metastatic cancer growth by manipulating how cells acquire their cholesterol.”
“Cancers persist by adapting to live in new tissues and organs, and we found that pancreatic tumors use PCSK9 to adapt as they spread.”
This revelation offers a potential new target for therapeutic intervention. By targeting PCSK9, researchers hope to disrupt the ability of pancreatic cancer cells to adapt and spread, ultimately improving treatment outcomes for this challenging disease.
Understanding Pancreatic Cancer and Metastasis
Frequently Asked Questions About Pancreatic Cancer
What are the early symptoms of pancreatic cancer?
Early symptoms of pancreatic cancer are often vague and can include abdominal pain, jaundice (yellowing of the skin and eyes), weight loss, and loss of appetite. As these symptoms can be caused by many different conditions, pancreatic cancer is frequently enough diagnosed at a later stage.
How is pancreatic cancer typically treated?
Treatment for pancreatic cancer depends on the stage of the cancer and may include surgery, chemotherapy, radiation therapy, or a combination of these. Targeted therapies and immunotherapies are also being explored in clinical trials.
What are the risk factors for pancreatic cancer?
Risk factors for pancreatic cancer include smoking, obesity, diabetes, chronic pancreatitis, and a family history of pancreatic cancer. Certain genetic syndromes can also increase the risk.
sources
